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Abstract
Background: In Iran, zoonotic and anthroponotic cutaneous leishmaniasis (CL) are caused by Leishmania major and L. tropica 
respectively. Despite extensive studies, no effective therapies have ever been reported for CL. The main objective of this research 
was to determine and compare the three different protocols for treatment of CL patients referring to Skin Diseases and Leishmaniasis 
Research Center (SDLRC), affiliated to Isfahan University of Medical Sciences, Isfahan, Iran from September 2017 to October 2018. 
Methods: In a randomized controlled parallel groups clinical trial, 150 selected CL patients who met our inclusion criteria were 
randomly assigned to one of the three therapy groups: A, intra-lesional glucantime plus 50% trichloroacetic acid (TCA), B, intra-
lesional glucantime and C, systemic glucantime. All patients in the three groups received the complete course of treatment and were 
followed for 6 months. To identify the etiologic agents, smears from their lesions were prepared and PCR-RFLP was used after parasite 
culture. Also, clinical characteristics, history of previous involvement, endemic emigration and demographic data were collected. 
Results: The results showed that the mean value of healing period was 53.12 ± 25.88 (median: 45, IQR: Q1 = 30-Q3 = 77) days in 
group A, 57.22 ± 44.02 (median: 42.5, IQR: Q1 = 30-Q3 = 60) days in group B, and 73.56 ± 41.08 (median: 71, IQR: Q1 = 45-Q3 
= 90) days in group C; the observed differences were statistically significant (P = 0.024).  There was a significant difference between 
group A and group C (P = 0.049), and between group B and group C (P = 0.047) in terms of mean healing period. Finally, complete 
recovery rates of 80%, 62% and 42% were shown in the three medicinal groups of A, B and C, respectively (P = 0.022). 
Conclusion: In this study, the average duration of lesion healing among the three groups was the shortest in patients with IL 
glucantime plus 50% TCA treatment regimen. Also, the use of 50% TCA in patients suffering from CL was associated with a significant 
improvement in the depth of scars, the time and the percentage of recovery, and the low cost of this agent in the treatment of CL. 
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Leishmaniasis, a sandfly-borne disease, is caused by 
different species of intracellular parasites of the genus 
Leishmania, which are transmitted to mammalian hosts 
after completion of their metacyclogenesis cycle in the 
gut of sandfly vectors. They nest into reticuloendothelial 
cells of vertebrate hosts where they are transformed into 
amastigotes.1 Involvement with leishmaniasis has been 
reported around the world with the exception of the 
islands of Oceania. The disease is estimated to affect 
about 12 million people in about 100 countries, and more 
than 350 million people are at risk. The annual rate of 
new occurrence in the world is about 1.5 to 2 million. 
Cutaneous leishmaniasis (CL) is one of the most neglected 
diseases and many cases of the disease are not reported 
annually. The predominant clinical form of the disease is 
CL with a prevalence of about 70%–75%. This form is 
very common in Central Asia, the Americas south of the 
United States, Africa and the Indian subcontinent.1-3  L. 
major and L. tropica cause zoonotic CL and anthroponotic 
CL in Iran, respectively. Occasionally, L. infantum has 
been reported as an etiologic agent of CL. People with 
zoonotic CL in Iran are about 20 000 cases annually; some 
believe that the number of involved cases is higher and it is 
the most important parasitic disease in this country.4 
Leishmaniasis treatment requires a multi-factorial 
approach. Clinical and epidemiological types of the 
disease, overlapping infections, parasite types, and 
geographical environments are important variables that 
must be addressed before protocols of effective therapy are 
implemented. While leishmaniasis is a treatable disease,5 
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because of multiple factors. The drug of choice for the 
treatment of all types of leishmaniasis is pentavalent 
antimonials (SbV), especially glucantime. Impairing 
the synthesis of ATP and GTP from ADP and GDP in 
Leishmania amastigotes reduces the parasite’s viability. 
This action takes place through inhibition of glycolysis 
and citric acid cycle and inhibition of glycolytic activity 
and fatty acid oxidation by antimonial compounds. 
Trichloroacetic acid (TCA) is an appropriate and usual 
topical treatment for many skin lesions. TCA can penetrate 
into the midreticular dermis and destroy the epidermis and 
dermis lesions up to the top surface of the epidermis. After 
treating ulcers with TCA, accelerated cellular generation 
appears within two weeks, proving that its application in 
ulcers due to CL can revolutionize the treatment process.6 
Dowlati reported that some cases of CL with skin lesions 
who did not respond to SbV compounds required a variety 
of treatments.7 One accompanying treatment for CL is 
using 50% TCA.7 Due to complications of high doses of 
meglumine antimoniate, using topical complementary 
compounds such as TCA 50% can be effective in prevention 
of scar formation.8,9 However, there are have been reports 
of complications due to using this agent. One of the most 
important factors associated with disease treatment is the 
species of the etiologic agent. Polymerase chain reaction 
(PCR) is an efficient tool to identify the etiologic agents 
of CL in patient-derived samples.10 Speciation of isolated 
organisms up to the species level is possible through some 
developed molecular methods.11,12 Three genes, including 
the internal transcribed spacer (ITS1) of the ribosomal 
DNA (rDNA),11,13,14 RNA 7SL,15,16 and heat shock 
protein70 genes (Hsp70) have been fully described in the 
scientific literature for identification of Leishmania isolates 
from endemic regions.17-20 Gene sequencing is globally 
validated as a method of choice for use in molecular, 
clinical, and epidemiological studies.21 The main objective 
of this study is comparison of three different therapies for 
CL and identification of the etiologic isolates in Isfahan, 
Iran. In this study, the nucleotide variations of ITS1 
sequences were used to characterize the agent parasite. 
Materials and Methods
Study Design and Participants
This randomized clinical parallel groups trial was carried 
out in the Isfahan province, Iran, from September 2017 
to October 2018 on CL-positive patients who referred 
to Skin Diseases and Leishmaniasis Research Center 
(SDLRC). In central Iran, the province of Isfahan lies 
between the central Zagros mountain range and the great 
desert. It occupies an area of around 107 000 km2 between 
latitudes 30° 42′ and 34° 30′ N and longitudes 49° 36′ and 
55° 32′ E. 
The inclusion criteria were positive direct slide 
microscopy of CL with no history of CL treatment. The 
exclusion criteria were pregnancy, and age under one year 
or above 90 years. In this study, the positive cases of CL 
were referred to the specialized laboratory of leishmaniasis 
to characterize the etiologic agents. The sample size of the 
study was determined by considering type one error rate α 
= 0.05, statistical power, 1-β = 0.8, and mean duration of 
treatment as one of the main outcomes to be 6.8 ± 1.7 and 
5.2 ± 1.0 weeks in glucantime and glucantime plus 50% 
TCA and complete cure rate 40% and 90%, respectively 
in the mentioned groups,6,22 resulting in 45 patients for 
each group; finally, 50 patients were recruited. Among 389 
patients suspected of CL, 150 positive patients identified 
by smear preparations were recruited. The total sample 
size was randomly allocated by using permutated block 
randomization method of size 6 to intervention groups 
equally. 
Demographic Data
Some demographic data (gender, age and habitat), clinical 
status contained location ( body organ, history of previous 
CL, endemic emigration) of and the onset of lesions, 
duration, traveling to endemic regions and history of 
previous involvement were collected. 
Smear Preparation
Smears were taken from the margins of the suspected 
leishmanial ulcers using No. 15 bistoury blade scalpels. For 
each patient, several smears were prepared. After drying at 
room temperature and fixing with methanol, they were 
stained with Giemsa dye solution, washed and examined 
with light microscopy to find parasitic amastigote forms.
Culture
For isolation and mass production of the leishmanial 
agents, skin samples were taken from the patients. To do 
this, the skin ulcers was washed with a local antiseptic 
solution, then the samples were removed with a sterile 
surgical razor and transferred to the culture medium, 
Novy-MacNeal-Nicolle (NNN); the cultures were 
incubated at 24 ± 1°C. They were then sub-cultured in a 
complemented RPMI 1640 cell culture medium (Gibco-
BRL) containing 10% fetal calf serum (Sigma-Aldrich).23 
Promastigotes were grown in the culture medium until 
late logarithmic phase, then centrifuged at 3000 rpm for 




DNA was extracted from the washed promastigotes as 
follows: Promastigotes (5 × 106) were suspended in 200 
µL of sterile PBS, 200 µL of binding buffer, and 40 µL of 
proteinase K and then incubated at 70°C for 10 minutes. 
DNA was dissolved in 200 µL of distilled water or 200 µL 
of elution buffer, and then extracted. DNA was run on a 
0.8% agarose gel at 80 V in tris/borate/EDTA (TBE) 1× 
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buffer for 20 to 40 minutes and then visualized under UV 
light after staining with GelRed.
Amplification of ITS1 Gene by PCR
Ribosomal ITS1 containing small subunit of (SSU) 
ribosomal RNA (rRNA) and 5.8 S rRNA regions were 
amplified using the following primers: 
1. LITSr (5’-CTGGATCATTTTCCGATG-3’) 
2. L5.8s (5’-TGATACCACTTATCGCACTT-3’).24-26 
DNA amplification was carried out in a 50 µL reaction 
mix of 200 µM deoxyribonucleotide triphosphates 
(dNTPs), 2.0 mM MgCl2, 2 U Taq polymerase (Roche 
Biotech, Germany), 10 pmol of each primer, and 100 ng of 
extracted DNA. The amplification stages were as follows: 
initial 5-minute denaturation at 95°C accompanied by 
30 cycles of 95°C for 20 seconds, 50°C for 30 seconds, 
and 72°C for 1 minute, plus 72°C for 6 minutes after 
extension. Ten microliters of the PCR product was used 
alongside a 50-base pair (bp) ladder on a 1% agarose gel 
containing GelRed at 80 V for 25 to 45 minutes. The gel 
was placed on a UV trans illuminator and compared with 
Leishmania reference strains.25,27
RFLP Analysis of Amplified ITS1 
The PCR products along with DNA of reference strains of 
L. major (MRHO/IR/ 75/ER), L. tropica (MHOM/IR/99/
YAZ1) and L. infantum (MCAN/IR/97/LON49) were 
digested with HaeIII (Fermentas, Leon-Rot, Germany) at 
37°C for 2 hours. Restriction fragments were placed onto 
2% agarose gels in 1×TBE buffer and visualized on a UV 
transilluminator after staining with GelRed.11,25,27
Patient Treatment by Different Protocols
A) IL Glucantime Plus 50% TCA
Periodic treatment of ulcer location with 50% TCA every 2 
weeks, with and topical glucantime injections twice a week 
in between were performed until complete wound healing 
or complete epithelization of the lesion for a maximum 
duration of 8 weeks. In topical treatment with 50% TCA, 
the site of the lesion was defatted with warm soap water 
and then 50% TCA was applied to the lesion using a 
cotton-head applicator embedded in TCA solution. After 
whitening, the position was neutralized with water and 
rubbed on with vaseline.8
B) IL Glucantime
IL glucantime injection was performed twice a week before 
the lesions were completely healed up to eight weeks later. 
IL injection was performed from the safe margin of the 
ulcer in quantities sufficient to blanch the lesion and 1 
mm surface of normal skin surrounding it.8
C) Systemic Glucantime
The first course of treatment was 20 mg/kg of glucantime 
for 21 days followed by a 10–14-day rest period. 
Afterwards, if the ulcer did not improve, direct smear was 
performed and then systemic glucantime injections were 
repeated up to three times.8
All patients in the three groups who received the 
complete course of treatment were followed for 6 months.8 
Complete healing was described as disappearing induration 
and complete ulcer re-epitheliazation.28
Outcome Measures
Monthly follow-up for the next 6 months was performed 
for all patients in the three medicinal groups. The clinical 
response was graded as total improvement (full lesion 
re-epithelialization), partial improvement (50%–75% 
lesion size improvement), and no difference in the lesion 
appearance. Scar improvement was also measured based 
on the patient’s satisfaction, the lesion morphology, and 
the induration level.6
Statistical Analysis
The SPSS statistical software (Ver16, Chicago, IL, USA) 
was used for data entry. Continuous data were reported 
as mean ± standard deviation (SD) along with median 
(interquartile range (IQR): first quartile(Q1)-third quartile 
(Q3) for non-normal continuous data). Normality of data 
was evaluated using Kolmogorov-Smirnov test and Q-Q 
plot, and homogeneity of variance was evaluated using 
Leven test. Non-normally distributed continuous data 
were subjected to logarithmic transformation. Chi-square 
test was performed to determine significant differences 
between the three study groups for categorical data and 
Fisher exact test was used when more than 20% of crosstab 
cells were expected to have a frequency less than 5. The 
effect of treatment approach on complete recovery was 
evaluated using logistic regression, and odds ratios (OR) 
and 95% confidence intervals (95% CI) for OR were 
reported. Both crude and adjusted ORs, after adjusting 
for the confounders, were reported. One-way analysis of 
variance (ANOVA) was used for comparing continuous 
data between the groups, followed by Tukey’s post-hoc test 
for pairwise group comparisons. Analysis of covariance 
was used for comparing the mean duration period when 
adjustment was made for confounders. Statistical analysis 
for main outcomes was conducted based on an intention-




In this study, all of the CL suspicious patients referred to 
SDLRC were investigated. Out of 389 patients suspected 
of CL, 180 did not fulfill the inclusion criteria and 54 did 
not agree to participate in our study. Finally, 150 patients 
confirmed through direct sampling and microscopic 
investigations were recruited and completed the study. 
Figure 1 presents the information on distribution, 
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randomization, exclusion, and final number of patients 
evaluated in the three groups. 
Basic Demographic & Clinical Characteristics 
The number of patients in group A was 20 females (40%) 
and 30 males (60%). Group B included 20 females (40%) 
and 30 males (60%), while group C included 19 females 
(38%) and 31 males (62%). The chi-square test illustrated 
that groups were not significantly different in terms of sex 
distribution (P = 0.972). 
As shown in Table 1, the mean age values of the subjects 
in the three groups were 33.64, 33.62 and 31.2 years, 
respectively.  In all three studied groups, the majority of 
participants were male. The majority of participants in 
treatment groups had low educational levels. Legs and 
arms were the two most affected organs among the studied 
participants in the three groups. History of previous CL 
was positive only in 4% and 8% of patients treated with 
IL glucantime plus 50% TCA (A) and IL glucantime (B), 
respectively, and none of the participants in the systemic 
glucantime group (C). Many of participants (more the 
70%) in all three studied groups had history of emigration 
to endemic areas. 
Smear Preparation
Among 389 CL suspected patients, 150 CL positive cases 
were selected via direct microscopy after Giemsa staining 
of slides containing impression smears from their lesions.
Table 1. Basic Demographic and Clinical Characteristics of Patients with CL 







Age 31.16 ± 19.76 33.62 ± 18.58 33.64 ±19.37
Gender
Female 20 (40) 20 (40) 19 (38)
Male 30 (60) 30 (60) 31 (62)
Education
Illiterate 13 (26) 20 (40) 13 (26)
Below diploma 19 (38) 9 (18) 17 (34)
High school diploma 15 (30) 16 (32) 17 (34)
University education 3 (6) 5 (10) 3 (6)
Body organ
Arm 21 (42) 29 (58) 17 (34)
Leg 22 (44) 13 (26) 18 (36)
Face 6 (12) 4 (8) 10 (20)
Neck 0 (0) 0 (0) 1 (2)
Trunk 1 (2) 4 (8) 4 (8)
History of previous CL 2 (4) 4 (8) 0 (0)
Endemic emigration 37 (74) 37 (74) 46 (92)
Continuous and categorical data are presented as mean ± SD and frequency 
(percentage), respectively.
 
Assessed for eligibility (n=389) 
Excluded (n=239) 
   Not meeting inclusion criteria (n=180) 
   Declined to participate  (n=59) 
Analysed (n= 50) 
Lost to follow-up (n=0) 
Discontinued intervention 
(n=0) 
Allocated to intervention 
(n=50) 
 Received allocated 
intervention (n=50)  
) 
Lost to follow-up (n= 0) 
Discontinued intervention 
(n= 0) 
Allocated to intervention 
(n=50) 
 Received allocated 
intervention (n=50) 







Allocated to intervention 
(n=50) 
 Received allocated 
intervention (n=50 ) 





Figure 1. Flow Diagram of Patient Recruitment.
Parasite Culture
For parasite isolation, samples were taken from the 
protruded margin of the ulcers under sterile conditions 
and cultured in screw capped tubes of N.N.N medium. 
The tubes were then incubated at 24ºC from 1 to 4 
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weeks until movable promastigotes appeared. For mass 
production of promastigotes, they were passaged into the 
complete RPMI 1640 medium.
Molecular Identification
The PCR Results of ITS1-rRNA and PCR-RFLP
The appearance of 350 bp bands related to isolates in 
conventional PCR were in agreement with the band 
extracted from the reference L. major  (Figure 2). When 
these bands were digested with HaeIII restricted enzyme, 
two bands of 220 and 140 bp appeared with complete 
homology to the reference strain, L. major (MRHO/IR/75/
ER). Other references strains were L. tropica (MHOM/
IR/99/YAZ1, lane 2) and L. infantum (MCAN/IR/97/
LON49, lane 3). Therefore, it was concluded that all the 
isolates obtained from patients were L. major (Figure 3).
CL Healing Period and Percent Recovery in the Three 
Medicinal Groups
Figure 4 shows the mean healing period of CL lesion in 
the three groups. The mean duration of healing period 
Figure 2. Conventional PCR results of Reference Strains Along with Three 
Isolates from Patients. M lane: DNA ladder 100 bp, lane 1: reference strain 
of L. major. lane 2: reference strain of L. tropica and lane 3: reference strain 
of L. infantum. Lane 4, 5, 6, 7, 8: patient’s specimen. Lane 9: negative 
control. 
Figure 3. PCR Results of PCR-RFLP of Reference Strains Along with Three 
Isolates from Patients. M lane: DNA ladder 50bp, lane 1: reference strain 
of L. major. lane 2: reference strain of L. tropica and lane 3: reference strain 
of L. infantum. Figure 4. Mean Duration of Lesion Healing in the Three Study Groups.
was 53.12 ± 25.88 (median: 45, IQR: Q1 = 30-Q3 = 
77) days in group A, 57.22 ± 44.02 (median: 42.5, IQR: 
Q1 = 30-Q3 = 60) days in group B, and 73.56 ± 41.08 
(median: 71, IQR: Q1 = 45-Q3 = 90) days in group C; 
the observed differences were statistically significant (P = 
0.024). After adjustment for the confounding effect of 
endemic emigration, the observed differences remained 
significant (P = 0.036).
The results of Tukey’s HSD post hoc test showed that 
there were no significant differences between group A 
and group B (P = 0.99); however, there was a significant 
difference between group A and group C (P = 0.049), and 
between group B and group C in terms of mean healing 
period (P = 0.047). However, after adjusting for the 
confounding variable (emigration to endemic area), only 
the difference between IL glucantime and IL glucantime 
plus 50% TCA was statistically significant (P = 0.022), the 
difference between Systemic glucantime and IL glucantime 
plus 50% TCA was not statistically significant (P = 0.057) 
and no significant difference was observed between 
Systemic glucantime and IL glucantime (P = 0.99).
Figure 5 shows the recovery status of lesions in the 
three studied groups. Chi-square test showed there were 
significant differences between the three groups in terms 
of healing of lesions (P = 0.002). In group A, 40 (80%) 
of patients showed complete recovery, 8 (16%), partially 
recovery and 2 (4%) no recovery. In group B, 31 (62%) 
had complete recovery, 12 (24%) partial recovery and 7 
(14%) no recovery. In group C, 21 (42%) had complete 
recovery, 22 (44%) partial recovery and 7 (14%) no 
recovery. 
The odds (95% CI) of complete recovery in group 
A were significantly higher OR = 6.67 (1.27–34.98) 
(adjusted OR = 5.64, 95% CI: 2.25–14.13) than 
group C (P = 0.025). Furthermore, although the crude 
odds of complete recovery were higher in group B than 
group C, OR =1.48 (0.45–4.85) the difference was not 
statistically significant; however, after adjusting for the 
effect of the confounding variable (emigration to endemic 
area), it was statistically significant (adjusted OR = 2.30, 
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95% CI: 1.02–5.20). The odds of complete recovery in 
patients of group A were higher than group B OR = 4.52 
(0.88–23.28); however, the difference was not statistically 
significant in either crude or adjusted models (adjusted 
OR = 2.45, 95% CI: 0.98–6.03) (P = 0.079).
Discussion
CL is reported in more than 90 countries, and Iran is 
an important focus of the disease. So far, no medication 
has been reported to induce complete recovery against 
leishmaniasis. Therefore, intensive research should be 
performed in pharmacological fields to achieve desired 
results. Antimony compounds have been introduced 
as the drug of choice for treatment of CL. Due to the 
complications of systemic administration of high doses 
of antimony compounds, application of local compounds 
such as 50% TCA has been considered. The healing effect 
of 50% TCA plus glucantime has been reported as an 
effective combination in reducing the scars and increasing 
the efficacy of glucantime.8 Following the evolution of 
numerous studies for better understanding the compounds 
or drug combinations to treat leishmaniasis, in this unique 
design, the comparison of the therapeutic effect of the 
three methods used for the treatment of CL patients was 
designed and implemented.
Parasite taxonomy appears to be necessary to properly 
understand the epidemiological changes based on 
population structure, genetic variation of the parasite 
and to determine the exact treatment regimen.29 For 
assessment of prognosis and effective care, early diagnosis 
and speciation of the etiologic parasite are critical.30 
Species identification is very useful in deciding the correct 
care scheme and disease prevention plans.31 In recent 
years, molecular methods such as PCR have been used 
for detection of the disease agents. It has been shown 
that molecular methods have higher specificity than the 
traditional culture methods.32 In the present study, the 
frequency distribution of species in the three treatment 
groups was identified as L. major by PCR method. Afkar 
et al in Bam city of Iran showed that 91.1% of the species 
were L. tropica and 8.9% were L. major.33 Pagheh et al in 
Golestan province of Iran showed that all of the specimens 
were L. major.34 Vaeznia et al in Mashhad province of Iran, 
used PCR-RFLP and detected 34% L. major and 66% L. 
tropica as agents of CL in a sample of 50 patients.35 Eslami 
et al in Yazd, Iran, identified 49.01% of samples to be L. 
major and 50.98% to be L. tropica.36
People traveling and moving over the time have caused 
epidemiological changes and created new foci in some 
parts of Iran. For example, a focus of L. major was created 
in Pakdasht, Tehran due to people traveling to Sabzevar 
city (a focus of L. major).37 Significant differences were 
found in terms of traveling to endemic areas among the 
three treatment groups in this study.
Glucantime (meglumine antimoniate) is a pentavalent 
antimony component and is the most commonly used 
drug for treatment of CL.38 We showed that the therapeutic 
effect of IL glucantime plus 50% TCA solution was 
significantly better than IL and systemic glucantime. 
However, the healing effect was better in the IL glucantime 
group compared to the systemic glucantime group.
Previously, the efficacy of IL glucantime has been shown 
for treatment of CL and it was shown that IL injection 
of glucantime does not reduce the therapeutic effect of 
the drug as compared to its systemic injection, while the 
side effects of IL injection were reduced.39,40 In our study, 
decreased induration, clinical healing of the lesions, and 
the reappearance of epidermis lines were more than 80%. 
Tallab et al investigated the effects of three IL glucantime 
injections daily, every other day, and weekly. The results 
showed that daily IL glucantime injection was more 
effective than treatment on every other day or on a weekly 
basis.41 Hejazi et al showed that IL glucantime injection 
that was performed weekly resulted in the resolution 
of CL ulcers. In the first treatment course, the patients 
received 20 mg/kg of glucantime for 21 days, and then, 
a rest period of 10–14 days, and then IL injections were 
performed for 5–7 weeks.42 
Some discrepancy observed across similar studies is 
























without improvement partial improvement complete improvement
Figure 5. Percent Recovery of Lesions in Treated Groups.
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et al, there is a significant relationship between glucantime 
activity in the lesions of non-infected CL and secondary 
bacterial infection. In other words, in bacterial infected 
lesions, the treatment response was reduced.43 Alkhavajah 
et al showed that the presence of secondary bacterial 
infection can lead to lack of response to treatment. 
Therefore, in this situation, before repetition of antimony 
treatment, secondary bacterial infection should be treated 
with appropriate antibiotic therapy.22 
It has been shown that the efficacy of IL therapy 
with five-compound antimony is 68–100%,22,44 which 
is approximately in agreement with our results (62% 
complete recovery). However, Faghihi et al reported 
that the rate of complete recovery of the lesions with IL 
glucantime injection was 41.7%.45 
If there is no glucantime available or there is susceptibility 
to glucantime or if treatment with this drug fails, an 
alternative local supplemental drug will be 50% TCA 
solution.8 Nilforoshzadeh et al showed that the use of 50% 
TCA resulted in significant healing in scars, time, and 
recovery percentages.8 The findings of a study by Cho et al 
indicate that treatment of atrophic scars through chemical 
reconstruction of skin scars (CROSS) is more successful 
than the simple application of TCA in the activation of 
fibroblasts in the dermis and in the increase of collagen.46
Considering that the best therapeutic effect was observed 
in group A in our study, it may be concluded that TCA, 
due to its acidic properties, reduces the tissue barrier in the 
proportional glucantime penetration and thus facilitates 
the delivery of glucantime to target cells. In addition, TCA 
alone can degrade parasite-infected macrophages in CL 
lesions. Other properties to be mentioned about this agent 
are suitable penetration of the dermis and destruction of 
scar lesions, stimulating and increasing the rate of cell 
proliferation, including fibroblast repair cells and skin 
collagen within two weeks after use and removing the scars 
caused by the disease. 
The results of this study regarding the effect of treatment 
approaches reflected in odds ratios should be interpreted 
with caution due to the small sample size and sparsity of 
data and possibly sparse data bias.47 Also, although the 
current study is a randomized clinical trial and it is expected 
that through randomization, the potential confounders to 
be balanced between study groups, due to the apparent 
sparsity in our data, we could not adjust for the confounding 
effects of some limited unbalanced confounders across the 
intervention groups. Accordingly, more studies with large 
sample sizes are suggested to confirm our results. Another 
limitation of our study is the lack of previous data about 
the effect of systemic glucantime on CL; accordingly, the 
sample size was determined based on available data about 
the effects of glucantime and glucantime plus 50% TCA.
In conclusion, in this study, the average duration of 
lesion healing among the three groups was the shortest 
in patients with IL glucantime plus 50% TCA treatment 
regimen. Also, treatment with IL glucantime plus 50% 
TCA, IL glucantime and systemic glucantime caused lesion 
healing in 80%, 62%, and 42% of cases, respectively. In 
the present study, use of 50% TCA in patients suffering 
from CL was associated with a significant improvement in 
the depth of scars, the time and the percentage of recovery 
and the low cost of this agent in treatment of CL. 
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